{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:54:43Z","timestamp":1760144083519,"version":"build-2065373602"},"reference-count":41,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2024,3,20]],"date-time":"2024-03-20T00:00:00Z","timestamp":1710892800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003569","name":"Ministry of Food and Drug Safety","doi-asserted-by":"publisher","award":["22183MFDS443","HV23C0074","HV23C1857"],"award-info":[{"award-number":["22183MFDS443","HV23C0074","HV23C1857"]}],"id":[{"id":"10.13039\/501100003569","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Korean Health Technology R&amp;D Project","award":["22183MFDS443","HV23C0074","HV23C1857"],"award-info":[{"award-number":["22183MFDS443","HV23C0074","HV23C1857"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>Varicella-zoster virus (VZV) poses lifelong risks, causing varicella and herpes zoster (HZ, shingles). Currently, varicella and HZ vaccines are predominantly live attenuated vaccines or adjuvanted subunit vaccines utilizing VZV glycoprotein E (gE). Here, we propose our vaccine candidates involving a comparative analysis between recombinant baculoviral vector vaccines (AcHERV) and a live attenuated vaccine strain, vOka. AcHERV vaccine candidates were categorized into groups encoding gE only, VZV glycoprotein B (gB) only, or both gE and gB (gE-gB) as AcHERV-gE, AcHERV-gB, and AcHERV-gE-gB, respectively. Humoral immune responses were evaluated by analyzing total IgG, IgG1, IgG2a, and neutralizing antibodies. Cell-mediated immunity (CMI) responses were evaluated by enzyme-linked immunospot (ELISPOT) assay and Th1\/Th2\/Th17 cytokine profiling. In the mouse model, AcHERV-gE-gB elicited similar or higher total IgG, IgG2a, and neutralizing antibody levels than vOka and showed robust VZV-specific CMI responses. From the perspective of antigens encoded in vaccines and their relationship with CMI response, both AcHERV-gB and AcHERV-gE-gB demonstrated results equal to or superior to AcHERV-gE, encoding only gE. Taken together, these results suggest that AcHERV-gE-gB can be a novel candidate for alleviating risks of live attenuated vaccine-induced latency and effectively preventing varicella during early stages of life while providing strong CMI for effective resistance against HZ and therapeutic potential in later stages of life.<\/jats:p>","DOI":"10.3390\/vaccines12030333","type":"journal-article","created":{"date-parts":[[2024,3,20]],"date-time":"2024-03-20T09:14:33Z","timestamp":1710926073000},"page":"333","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Baculovirus Vector-Based Varicella-Zoster Virus Vaccine as a Promising Alternative with Enhanced Safety and Therapeutic Functions"],"prefix":"10.3390","volume":"12","author":[{"given":"Chanyeong","family":"Lee","sequence":"first","affiliation":[{"name":"Department of Biomedical Science and Engineering, Konkuk University, Seoul 05029, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minjee","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Biomedical Science and Engineering, Konkuk University, Seoul 05029, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jungmin","family":"Chun","sequence":"additional","affiliation":[{"name":"Department of Biomedical Science and Engineering, Konkuk University, Seoul 05029, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sehyun","family":"Kim","sequence":"additional","affiliation":[{"name":"KRBioTech, Seoul 05029, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Doyoung","family":"Yoon","sequence":"additional","affiliation":[{"name":"Department of Biomedical Science and Engineering, Konkuk University, Seoul 05029, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyeondong","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Biomedical Science and Engineering, Konkuk University, Seoul 05029, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heewon","family":"Bang","sequence":"additional","affiliation":[{"name":"Department of Biomedical Science and Engineering, Konkuk University, Seoul 05029, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hee-Jung","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Biomedical Science and Engineering, Konkuk University, Seoul 05029, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3190-1333","authenticated-orcid":false,"given":"Hosun","family":"Park","sequence":"additional","affiliation":[{"name":"Department of Microbiology, College of Medicine, Yeungnam University, Daegu 42415, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1681-5557","authenticated-orcid":false,"given":"Young Bong","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Biomedical Science and Engineering, Konkuk University, Seoul 05029, Republic of Korea"},{"name":"KRBioTech, Seoul 05029, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2024,3,20]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1099\/vir.0.007658-0","article-title":"Lineages of varicella-zoster virus","volume":"90","author":"McGeoch","year":"2009","journal-title":"J. Gen. Virol."},{"key":"ref_2","unstructured":"World Health Organization (2014). Varicella and herpes zoster vaccines: WHO position paper, June 2014. Wkly. Epidemiol. Rec., 89, 265\u2013287."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1056\/NEJMcp1302674","article-title":"Clinical practice: Herpes zoster","volume":"369","author":"Cohen","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_4","first-page":"58","article-title":"Neurologic complications of varicella-zoster virus reactivation in a person with HIV\/AIDS","volume":"17","author":"Archuleta","year":"2007","journal-title":"AIDS Read."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"S91","DOI":"10.1086\/342963","article-title":"Varicella-zoster virus: Atypical presentations and unusual complications","volume":"186","author":"Gnann","year":"2002","journal-title":"J. Infect. Dis."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s12979-019-0164-9","article-title":"Immunosenescence and human vaccine immune responses","volume":"16","author":"Crooke","year":"2019","journal-title":"Immun. Ageing"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1111\/j.1525-1497.2005.0150.x","article-title":"The incidence of herpes zoster in a United States administrative database","volume":"20","author":"Insinga","year":"2005","journal-title":"J. Gen. Intern. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1017\/S0950268801005921","article-title":"Epidemiology of varicella zoster virus infection in Canada and the United Kingdom","volume":"127","author":"Brisson","year":"2001","journal-title":"Epidemiol. Infect."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1080\/21645515.2020.1847582","article-title":"A systematic literature review of herpes zoster incidence worldwide","volume":"17","author":"Vroling","year":"2021","journal-title":"Hum. Vaccin. Immunother."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1016\/S0140-6736(74)90144-5","article-title":"Live vaccine used to prevent the spread of varicella in children in hospital","volume":"2","author":"Takahashi","year":"1974","journal-title":"Lancet"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2309985","DOI":"10.1080\/22221751.2024.2309985","article-title":"Herpes zoster mRNA vaccine induces superior vaccine immunity over licensed vaccine in mice and rhesus macaques","volume":"13","author":"Huang","year":"2024","journal-title":"Emerg. Microbes Infect."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"5793","DOI":"10.1016\/j.vaccine.2020.06.062","article-title":"Immunogenicity generated by mRNA vaccine encoding VZV gE antigen is comparable to adjuvanted subunit vaccine and better than live attenuated vaccine in nonhuman primates","volume":"38","author":"Monslow","year":"2020","journal-title":"Vaccine"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.virs.2022.06.002","article-title":"LNP-CpG ODN-adjuvanted varicella-zoster virus glycoprotein E induced comparable levels of immunity with Shingrix in VZV-primed mice","volume":"37","author":"Luan","year":"2022","journal-title":"Virol. Sin."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/s41541-021-00303-w","article-title":"Human endogenous retrovirus-enveloped baculoviral DNA vaccines against MERS-CoV and SARS-CoV2","volume":"6","author":"Cho","year":"2021","journal-title":"NPJ Vaccines"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1016\/j.vaccine.2022.12.067","article-title":"Baculoviral COVID-19 Delta DNA vaccine cross-protects against SARS-CoV2 variants in K18-ACE2 transgenic mice","volume":"41","author":"Jang","year":"2023","journal-title":"Vaccine"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.biotechadv.2011.04.004","article-title":"Baculovirus as a gene delivery vector: Recent understandings of molecular alterations in transduced cells and latest applications","volume":"29","author":"Chen","year":"2011","journal-title":"Biotechnol. Adv."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2847","DOI":"10.1128\/JVI.79.5.2847-2858.2005","article-title":"Involvement of the Toll-like receptor 9 signaling pathway in the induction of innate immunity by baculovirus","volume":"79","author":"Abe","year":"2005","journal-title":"J. Virol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1128\/JVI.03055-13","article-title":"Innate immune response induced by baculovirus attenuates transgene expression in mammalian cells","volume":"88","author":"Ono","year":"2014","journal-title":"J. Virol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"17297","DOI":"10.1038\/s41598-017-17609-2","article-title":"CpG-oligodeoxynucleotides developed for grouper toll-like receptor (TLR) 21s effectively activate mouse and human TLR9s mediated immune responses","volume":"7","author":"Yeh","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/S0167-7799(01)01911-4","article-title":"Recombinant baculoviruses as mammalian cell gene-delivery vectors","volume":"20","author":"Kost","year":"2002","journal-title":"Trends Biotechnol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1007\/s007050050364","article-title":"High-titre, cryostable cell-free varicella zoster virus","volume":"143","author":"Harper","year":"1998","journal-title":"Arch. Virol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1093\/infdis\/130.6.669","article-title":"Serologic response to varicella-zoster membrane antigens measured by direct immunofluorescence","volume":"130","author":"Williams","year":"1974","journal-title":"J. Infect. Dis."},{"key":"ref_23","first-page":"359","article-title":"Perspectives on vaccines against varicella-zoster virus infections","volume":"342","author":"Gershon","year":"2010","journal-title":"Curr. Top Microbiol. Immunol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"3094","DOI":"10.1128\/JCM.00719-06","article-title":"Serological detection of varicella-zoster virus-specific immunoglobulin G by an enzyme-linked immunosorbent assay using glycoprotein antigen","volume":"44","author":"Sauerbrei","year":"2006","journal-title":"J. Clin. Microbiol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1097\/WCO.0000000000000092","article-title":"Neurological complications of varicella zoster virus reactivation","volume":"27","author":"Nagel","year":"2014","journal-title":"Curr. Opin. Neurol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"15","DOI":"10.2147\/ITT.S176383","article-title":"Varicella zoster virus vaccines: An update","volume":"8","author":"Gabutti","year":"2019","journal-title":"Immunotargets Ther."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1586\/14760584.4.5.629","article-title":"Review of the Varilrix varicella vaccine","volume":"4","author":"Chiu","year":"2005","journal-title":"Expert Rev. Vaccines"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"241","DOI":"10.2147\/CIA.S1225","article-title":"Zoster vaccine live for the prevention of shingles in the elderly patient","volume":"3","author":"Zussman","year":"2008","journal-title":"Clin. Interv. Aging"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"103","DOI":"10.15585\/mmwr.mm6703a5","article-title":"Recommendations of the Advisory Committee on Immunization Practices for Use of Herpes Zoster Vaccines","volume":"67","author":"Dooling","year":"2018","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"S429","DOI":"10.1093\/infdis\/jiab387","article-title":"Herpes Zoster Vaccines","volume":"224","author":"Harbecke","year":"2021","journal-title":"J. Infect. Dis."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Cid, R., and Bolivar, J. (2021). Platforms for Production of Protein-Based Vaccines: From Classical to Next-Generation Strategies. Biomolecules, 11.","DOI":"10.3390\/biom11081072"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1128\/JVI.76.2.591-599.2002","article-title":"Role of the varicella-zoster virus gB cytoplasmic domain in gB transport and viral egress","volume":"76","author":"Heineman","year":"2002","journal-title":"J. Virol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1128\/JVI.01707-16","article-title":"The Glycoprotein B Cytoplasmic Domain Lysine Cluster Is Critical for Varicella-Zoster Virus Cell-Cell Fusion Regulation and Infection","volume":"91","author":"Yang","year":"2017","journal-title":"J. Virol."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Oliver, S.L., Xing, Y., Chen, D.H., Roh, S.H., Pintilie, G.D., Bushnell, D.A., Sommer, M.H., Yang, E., Carfi, A., and Chiu, W. (2021). The N-terminus of varicella-zoster virus glycoprotein B has a functional role in fusion. PLoS Pathog., 17.","DOI":"10.1371\/journal.ppat.1008961"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"9483","DOI":"10.1128\/JVI.75.19.9483-9492.2001","article-title":"Varicella-zoster Virus gB and gE coexpression, but not gB or gE alone, leads to abundant fusion and syncytium formation equivalent to those from gH and gL coexpression","volume":"75","author":"Maresova","year":"2001","journal-title":"J. Virol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"S58","DOI":"10.1086\/522123","article-title":"Humoral and cellular immunity to varicella-zoster virus: An overview","volume":"197","author":"Arvin","year":"2008","journal-title":"J. Infect. Dis."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"103","DOI":"10.4167\/jbv.2021.51.3.103","article-title":"Immune Responses to Varicella Zoster Virus and Effective Vaccines","volume":"51","author":"Lee","year":"2021","journal-title":"J. Bacteriol. Virol."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Mahalingam, R., Gershon, A., Gershon, M., Cohen, J.I., Arvin, A., Zerboni, L., Zhu, H., Gray, W., Messaoudi, I., and Traina-Dorge, V. (2019). Current In Vivo Models of Varicella-Zoster Virus Neurotropism. Viruses, 11.","DOI":"10.3390\/v11060502"},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Laemmle, L., Goldstein, R.S., and Kinchington, P.R. (2019). Modeling Varicella Zoster Virus Persistence and Reactivation\u2014Closer to Resolving a Perplexing Persistent State. Front. Microbiol., 10.","DOI":"10.3389\/fmicb.2019.01634"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/BF00350393","article-title":"Passage effect of virus infection in insect cells","volume":"20","author":"Krell","year":"1996","journal-title":"Cytotechnology"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2669","DOI":"10.1099\/vir.0.19438-0","article-title":"Spontaneous excision of BAC vector sequences from bacmid-derived baculovirus expression vectors upon passage in insect cells","volume":"84","author":"Pijlman","year":"2003","journal-title":"J. Gen. Virol."}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/12\/3\/333\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:16:43Z","timestamp":1760105803000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/12\/3\/333"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,20]]},"references-count":41,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,3]]}},"alternative-id":["vaccines12030333"],"URL":"https:\/\/doi.org\/10.3390\/vaccines12030333","relation":{},"ISSN":["2076-393X"],"issn-type":[{"type":"electronic","value":"2076-393X"}],"subject":[],"published":{"date-parts":[[2024,3,20]]}}}